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Alport syndrome, caused by mutations that interfere with the
normal assembly of the a3a4a5(IV) collagen network in the
glomerular basement membrane (GBM), is the most common
inherited glomerular disease leading to renal failure. A
detailed knowledge of the underlying pathogenic
mechanisms is necessary for developing new, more specific,
and effective therapeutic strategies aimed at delaying the
onset and slowing disease progression. Studies of several
dog and mouse models of Alport syndrome have significantly
enhanced our understanding of the disease mechanisms
and provided systems for testing potential therapies. In
the most widely used Col4a3/ mouse models of
autosomal-recessive Alport syndrome (ARAS), the genetic
background strongly affects renal survival. One contributing
factor may be the strong ectopic deposition of a5a6(IV)
collagen in the GBM of Col4a3-/- mice on the C57BL/6J
background, which is almost undetectable on the 129/Sv
background. This isoform ‘switch’ has not been observed in
human ARAS, although it had been reported in the dog
model of ARAS. In human patients as well as dog and mouse
models of X-linked Alport syndrome, the a3–a6(IV) collagen
chains are absent from the GBM. These biochemical
differences among Alport animal models provide an
opportunity to determine how the molecular makeup of the
GBM affects the glomerular function. At the same time,
potentially confounding influences of characteristics unique
to a particular strain or model should be carefully considered
in the design of studies aiming to define key events
underlying the pathobiology of Alport glomerular disease.
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The glomerular basement membrane (GBM) is an important
component of the glomerular filtration barrier. Its molecular
composition changes during glomerulogenesis. The embryo-
nic GBM contains a collagen IV network comprised of only
a1(IV) and a2(IV) chains. A developmental switch is
activated at the capillary loop stage of glomerular develop-
ment, resulting in expression and assembly of a3(IV), a4(IV),
and a5(IV) chains (Figure 1).1–3 In mature glomeruli, the
GBM consists of a relatively thin subendothelial a1a2(IV)
collagen network and a relatively thick subepithelial
a3a4a5(IV) collagen network. Alport syndrome is caused
by mutations in the COL4A3 or COL4A4 genes (in the
autosomal form of disease), or in the COL4A5 gene (in the
X-linked form), whereby functional inactivation of the gene,
mRNA, or protein leads to the defective assembly and often
the complete absence of all three chains in the GBM.4
Instead, the embryonic a1a2(IV) collagen is deposited
throughout the thickness of the mature Alport GBM. This
different molecular composition of the Alport GBM is the
underlying defect that somehow leads to the initiation of
glomerular disease during childhood or adolescence. Before
this unknown triggering event, the Alport GBM is slightly
thinner than normal. During this time there is no measurable
proteinuria and patients have a normal glomerular filtration
rate. Onset of the disease is characterized by progressively
increasing proteinuria associated with irregular thickening
and splitting of the GBM and podocyte foot process
effacement. Because the GBM functions normally in Alport
patients for a time, it seems possible that blocking the
event(s) that trigger disease initiation might arrest the disease
in its pre-pathogenic state. Thus, identification of the events
initiating disease, as well as those driving disease progression,
is central issue of current research efforts. Nearly all of this
work is being carried out using animal models.
Several spontaneous dog models for Alport syndrome
have been identified and characterized. The earliest described
and most studied is a model of X-linked Alport syndrome in
a Samoyed breed containing a stop codon in exon 35 of the
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COL5A5 gene.5 A second X-linked Alport model has been
described in a mixed breed of dogs from Navasota, Texas.6
Both of these models lack a3(IV), a4(IV), and a5(IV)
collagen chains in their GBM. A canine model for autosomal-
recessive Alport syndrome (ARAS) has been described;
however, the mutation has not yet been identified.7 In this
model, a3(IV) and a4(IV) collagen chains are missing from
the GBM, yet a5(IV) collagen is present (albeit at reduced
levels compared with normal littermates). Importantly,
a6(IV) collagen, which in normal kidneys is found only in
the basement membranes of the Bowman’s capsule and
collecting ducts, is ectopically present in the GBM of these
dogs. Expression of a6(IV) collagen had never been reported
in the GBM of any mammalian species, normal or diseased.
End-stage renal failure in these dogs occurs somewhat later
(12–18 months) than either the Samoyed model (8–10
months) or the Navasota model (10–15 months). However,
it is not known whether this is linked to the deposition of a5/
a6(IV) collagen in the GBM of this model.
Several mouse Alport models have also been described.
Two models for ARAS have been developed by gene targeting
at the Col4a3 locus.8,9 Both were initially characterized in a
mixed background, and have a similar pathologic profile in
the glomerulus. One of these models is commercially
available through the Jackson Laboratories on the 129/SvJ
background. More recently, a murine model for X-linked
Alport syndrome has been generated by introducing a G5X
mutation in the Col4a5 gene; these mutant mice are on the
C57BL/6 background.10 In the original description of these
different mouse models, all of them were reported to lack
expression of a3(IV), a4(IV), and a5(IV) collagen chains in
the GBM. The influence of the genetic background on the
timing of the onset of glomerular disease and the rate of
progression to end-stage renal failure was studied by back-
crossing autosomal Alport mice onto both the 129/SvJ and
the C57BL/6J backgrounds.11 C57BL/6 Col4a3–/– mice,
compared with 129 Alport mice showed a markedly delayed
disease onset (measurable proteinuria at 100 versus 35 days)
and end-stage renal failure (194 versus 66 days). After
backcrossing F1(129B6) hybrid mice to the parental
C57BL/6 strain, DNA from the resulting N2 mice with fastest
and slowest rates of renal progression was used in mapping
studies, identifying two quantitative trait loci that segregate
with the two extremes.11 The putative modifier loci were
located on chromosomes 9 and 16, but the responsible genes
have not yet been identified.
Very recently, strain-dependent differences in the GBM
composition of Col4a3/ mice were identified that may
also affect the rate of progression to renal failure.12 Slow-
progressing C57BL/6 Col4a3/ mice exhibited robust GBM
deposition of the a5(IV) collagen chain accompanied by the
ectopic a6(IV) collagen. The two chains were biochemically
associated with each other and with a1(IV) and a2(IV)
collagen, indicating co-assembly as an a1a2/a5a6(IV)
collagen network (Figure 1). Much lower amounts of
a5(IV) and a6(IV) collagen were detected in the GBM
of 129/Sv Col4a3/ mice; this was attributable to an
overall low synthesis or defective assembly of a6(IV)
collagen-containing networks in tissues from 129/Sv mice,
independent of the Alport mutation. In reciprocal
F1(B6x129) crosses of Col4a3/ mice, it was found that
strong GBM deposition a5/a6(IV) collagen was inherited in a
pattern consistent with X-linked transmission, and it
correlated with a 46% increase in the longevity observed in
C57BL/6 versus 129/Sv affected mice.12 By comparing the
GBM composition and renal survival in Col4a3/ mice on
pure and hybrid backgrounds, it was estimated that the
ectopic a5a6(IV) collagen in the Alport GBM contributes
about 28% of the added lifespan observed in C57BL/6 versus
129/Sv affected mice.
In contrast to observations in mouse and dog models of
ARAS, immunochemical studies of collagen IV chains in the
GBM of human patients with this form of disease have not
identified ectopic expression of a6(IV) collagen, nor the
presence of a5(IV) collagen.13,14 The variable expression of
a5/a6(IV) collagen in the autosomal-recessive Alport GBM –
ranging from strong in mutant B6 mice to moderate in
affected dogs, very weak in 129 mutant mice, and absent in
human patients raises the question of how this network
affects the glomerular function, the onset of disease, and its
rate of progression. The physico-chemical properties and
biological functions of extracellular matrices are determined
by their molecular makeup, and changes in composition
likely affect both cell adhesion and cell signaling. Because the
properties of the embryonic a1a2(IV) collagen network are
distinct from those of the adult a3a4a5(IV) network, it is
likely that the persistence of the embryonic a1a2(IV) collagen
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Figure 1 | Schematic diagram summarizing strain-dependent
differences in type IV collagen isoform switches in ARAS. Normal
embryonic GBM contains only a1a2(IV) collagen networks (red).
At the capillary loop stage of development in mice, a developmental
switch activates expression of the COL4A3, COL4A4, and COL4A5
genes, resulting in the assembly of a subepithelial collagen network
of a3a4a5(IV) chains (green), with a persistence of a subendothelial
network of a1a2(IV) chains (red). In the COL4A3/ mouse on the
C57BL/6 background, an alternative isoform switch results in robust
expression of a5a6(IV) networks in the GBM (blue). One report
suggests very weak expression of the a5a6(IV) network in the
COL4A3/ mouse on the 129 background (dashed line).12
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network in the GBM of Alport patients has multiple
consequences that culminate in glomerular disease initiation.
Fewer inter-chain cross-links in the a1/a2(IV) collagen
network15 likely affect its elasticity as well as susceptibility
to endoproteolytic cleavage,1 which may promote its eventual
breakdown. Furthermore, it has been shown that ectopic
laminins are deposited or re-deposited in the GBM of both
129/Sv and C57BL/6J autosomal Alport mice.16–18
Alterations of GBM composition likely contribute to
physical changes in the podocytes that lead to foot process
effacement and loss of the glomerular filtration barrier.
As podocytes normally adhere to the GBM containing
a3/a4/a5(IV) collagen, it is likely that podocytes might be
distinctively influenced by the presence of a1/a2(IV) in the
Alport GBM, which in turn may have different effects
than ectopic a5/a6(IV) collagen. Earlier studies have shown
altered gene expression in Alport glomeruli compared with
wild-type glomeruli. Podocyte-specific induction of mRNA
encoding transforming growth factor-a1 and matrix proteins
has been shown,19 and inhibition of transforming growth
factor-a1 results in reduced thickening of the GBM.18 More
recently, podocyte-specific induction of CCR2 and matrix
metalloproteinase-12 was demonstrated to contribute to the
GBM destruction associated with Alport syndrome.20 All of
these studies were performed in the 129/Sv autosomal Alport
mice and validated using necropsy specimen from human
Alport patients. It is possible that some of these observations
might not be recapitulated in C57BL/6 Alport mice. A
comparison of two recent studies using different strains of
Col4a3/ mice underscores this risk. One study performed in
129/Sv Alport mice documented no change in glomerular
expression of matrix metalloproteinase-2.20 The other study,
conducted in C57BL/6 Alport mice documented a significant
elevation of glomerular matrix metalloproteinase-2 expression.21
Thus, the results likely reflect strain-specific differences in the
regulation of a potentially important modulator of glomerular
pathogenesis.
The use of the C57BL/6 background does have certain
advantages. First, slower progression allows a wider window
for studying events associated with the initiation of
glomerular pathology. It also allows colony maintenance by
homozygous breeding, reducing the number of animals and
costs. Second, many knockout mouse strains carrying
mutations in genes of interest to investigators studying
Alport glomerular pathogenesis are in the C57BL/6 back-
ground, which simplifies the production of purebred mice
with multiple knockout mutations. Third, the availability of
both autosomal-recessive and X-linked Alport mice on the
C57BL/6 background, expressing different collagen IV net-
works in the mutant GBM, affords investigators a choice of
models with ‘customized’ GBM composition.
Finally, the existence of genetic modifiers documented
through the mapping of quantitative trait loci provides a
powerful incentive to study the C57BL/6 Alport mouse
models. In both X-linked and autosomal Alport mice on the
C57BL/6 background, the onset of proteinuria is not
observed until adulthood, whereas it occurs at the pre-
pubescent stage of life in all Alport dog models and in 129/Sv
Alport mice, as in human patients. Identification of the genes
responsible for the delayed onset of disease would provide
meaningful insights into understanding the molecular events
underlying glomerular pathogenesis in Alport syndrome, and
may provide the basis for developing novel therapeutic
strategies. On the other hand, basic studies aimed at defining
specific molecular pathways influencing glomerular disease
initiation and progression might be affected unpredictably by
the modifier effects, whereas the duration and expense of
studies testing novel therapeutic agents in C57BL/6 Alport
mice would be considerably increased.
All of us interested in exploring the mechanisms of Alport
glomerular pathogenesis aim to identify pathways relevant to
the human disease. In the coming years, it is likely that
exploitation of the existing animal model systems will yield a
wealth of information toward this end. If we do not choose
our model systems carefully, we run the risk of creating an
inchoate body of literature. This would surely hamper the
development of effective therapeutic strategies for what
should be a treatable disease.
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